| Revenue growth | 15% YoY Net Revenue growth. |
|---|---|
| Margins | Operating EBITDA margin steady at 24.8% in Q1 FY27. |
| Demand visibility | High; ~75% Q1 FY27 occupancy and low bed density in metros. |
| Management confidence | Strong; focused on bed capacity expansion and digital ecosystem. |
Growth
Network Gross Revenue grew 16% YoY to ₹2,982 Cr; Profit After Tax increased 3% YoY to ₹357 Cr.
Outlook
Targeting ~8,300 additional beds with ~4,000 in next 3-4 years; ₹6,961 Cr estimated expansion capex through FY30.
Risks
Potential impact of stricter doubtful debt provisions and integration risks from recent large-scale hospital acquisitions.
Last quarter's promises, checked
Delivered
- Guided 20% brownfield capacity rollout → delivered 20% (BEAT)
- Guided Kalinga Hospital integration in Q1 → delivered Consolidation started (BEAT)
- Guided Sector 56 Gurgaon commissioning by year-end → delivered On track (BEAT)
Partly delivered
- Guided Lucknow capacity to 570 beds in 2 quarters → delivered On track (PARTIAL)
- Guided CGHS rate revision flow-through → delivered Partial flow-in, balance pending (PARTIAL)
Investor Presentation filed with NSE, NSE: MAXHEALTH. Summary written with AI assistance from the document.
Max Healthcare Institute Ltd: key numbers
- Share price
- ₹1,014.00
- Market cap
- ₹98,694 Cr
- Revenue (annual)
- ₹8,373 Cr
- Net profit (annual)
- ₹1,442 Cr
- P/E (TTM)
- 67.7×Sector 57.8×
- Promoter holding
- 23.71%+0.00% QoQ
- FII holding
- 41.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Max Healthcare Institute Ltd
All →Max Healthcare Institute Annual General Meeting
Max Healthcare Institute Ltd issued a postal ballot notice to seek shareholder approval for its 2026 ESOP scheme, director remuneration, and alterations to its objects clause.
Max Healthcare Institute Other Announcement
Max Healthcare has received an ESG rating of '72' from Niche99, a SEBI-registered provider. This independent rating places the company in the 'Leader' category.
Max Healthcare Institute Legal & Regulatory
Max Healthcare disclosed an update on ongoing NCLT proceedings initiated by BRS Capital against its subsidiary. The next hearing is scheduled for September 28, 2026.
Max Healthcare Institute Employee Stock Options
Max Healthcare Institute Limited has allotted 33,765 equity shares under its ESOP scheme. This increases the total paid-up share capital to 973,310,251 equity shares.
Max Healthcare Institute Employee Stock Options
Max Healthcare allotted 33,765 equity shares under its Employee Stock Option Scheme 2022. The allotment was made at an exercise price of ₹350 per share.
- Value
- ₹1.18 Cr
Max Healthcare Institute Acquisition Worth ₹87.87 Cr
Max Healthcare Institute Limited approved an additional investment of Rs. 87.87 Crore in its subsidiary, Kalinga Hospital Limited. The funds will support capital expenditure and modernization programs.
- Value
- ₹87.87 Cr
- Execution
- Within next 15 days